

# Transfer of securities to BNP Paribas Arbitrage Issuance B.V. ("BNPP IBV") pursuant to Part VII of the UK Financial Services and Markets Act 2000

On 19 November 2015, The Royal Bank of Scotland plc (with its registered office at 36 St Andrew Square, Edinburgh, Scotland) ("RBS") and BNP Paribas S.A. (incorporated in France and with its registered office at 16, Boulevard des Italiens, 75009 Paris, France) ("BNPP"), acting through its London Branch, announced that the Court of Session in Scotland had approved and sanctioned the implementation of a banking business transfer scheme, whereby certain assets and liabilities related to RBS's structured retail investor products and equity derivatives business would be transferred to BNPP pursuant to Part VII of the UK Financial Services and Markets Act 2000 (the "Part VII Scheme").

The Part VII Scheme took effect on 7 December 2015 (the "Effective Date").

On the Effective Date, BNPP, acting through its London Branch, became the issuer of those securities originally issued by RBS that were transferred pursuant to the Part VII Scheme. Immediately after the transfer of those securities to BNPP, acting through its London Branch, the role of the issuer under those securities was transferred, also under the terms of the Part VII Scheme, to BNPP IBV, a wholly owned subsidiary of BNPP. As part of the Part VII Scheme, BNPP guarantees all the obligations of BNPP IBV arising in respect of the transferred securities.

Under the Part VII Scheme, amendments were made to the terms of the transferring securities and to agreements related to them from the Effective Date in order to give effect to the Part VII Scheme, including (but not limited to) references to "RBS", in its capacity as issuer of the transferred securities, being construed as references to "BNPP IBV".

Details of the securities that have transferred under the Part VII Scheme as well as further Part VII Scheme generally can viewed http://warrants.bnpparibas.com/



#### Transfer of securities to The Royal Bank of Scotland plc pursuant to General Conditions 8(a)

On 12 November 2012, The Royal Bank of Scotland N.V. ("RBS N.V.") issued a notice to holders of certain securities (including this security) of its intention to substitute The Royal Bank of Scotland plc, registered in Scotland under No. SC090312, with registered office at 36 St Andrew Square, Edinburgh EH2 2YB ("RBS plc") as issuer of the securities in place of RBS N.V., under the contractual right of substitution contained in General Condition 8(a) of the securities (the "Substitution"). The Substitution took effect on 13 December 2012 (the "Effective Date").

On 19 April 2011, the Boards of The Royal Bank of Scotland Group plc ("RBSG"), RBS plc, RBS Holdings N.V. and RBS N.V. announced that they had approved the proposed transfers of a substantial part of the business activities of RBS N.V. to RBS plc (the "Proposed Transfers"), subject, amongst other matters, to regulatory and other approvals, further tax and other analysis in respect of the assets and liabilities to be transferred and employee consultation procedures. Further information on the Proposed Transfers generally can be found at the following address: <a href="http://www.investors.rbs.com/RBS">http://www.investors.rbs.com/RBS</a> NV. The Proposed Transfers are consistent with The Royal Bank of Scotland Group plc's efforts to simplify its structure, thereby reducing risk, cost and complexity.

It was also announced that it was expected that the Proposed Transfers would be implemented on a phased basis over a period ending 31 December 2013 and that a large part of the Proposed Transfers, including the transfers of certain securities issued by RBS N.V., was expected to have taken place by the end of 2012. Where available and practicable, statutory transfer schemes have been used to implement the Proposed Transfers.

One statutory scheme used to implement the Proposed Transfers was the implementation of a banking business transfer scheme in respect of eligible business carried on in the United Kingdom by RBS N.V. pursuant to Part VII of the UK Financial Services and Markets Act 2000 (the "Part VII Scheme"). The Part VII Scheme took effect on 17 October 2011.

Another statutory scheme was used to transfer to RBS plc a substantial part of the business conducted by RBS N.V. in The Netherlands as well as in certain other EMEA branches of RBS N.V. That transfer was effected by way of a Dutch statutory demerger (the "Demerger") of the RBS N.V. transferring businesses to RBS II B.V. (a Dutch company licensed as a bank in The Netherlands that had been established specifically for the purposes of the Dutch Scheme), followed by the merger of RBS II B.V. into RBS plc by way of a cross-border merger (together with the Demerger, the "Dutch Scheme"). The Dutch Scheme was implemented on 10 September 2012.

This Substitution was a continuation of the Proposed Transfers.

## FINAL TERMS

**DATED 26 JULY 2012** 



# The Royal Bank of Scotland N.V.

(incorporated in The Netherlands with its statutory seat in Amsterdam)

1,000,000 AEX-INDEX® TURBO LONG CERTIFICATES

ISSUE PRICE: EUR 0.75

1,000,000 AEX-INDEX® TURBO LONG CERTIFICATES

ISSUE PRICE: EUR 0.43

THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR THE SECURITIES LAWS OF ANY STATE OR POLITICAL SUBDIVISION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR DELIVERED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY U.S. PERSON, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO THE REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE U.S. STATE SECURITIES LAWS. THE SECURITIES ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES TO PERSONS OTHER THAN U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) IN OFFSHORE TRANSACTIONS THAT MEET THE REQUIREMENTS OF REGULATION S UNDER THE SECURITIES ACT. FUTHERMORE, TRADING IN THE SECURITIES HAS NOT BEEN APPROVED BY THE UNITED STATES COMMODITY FUTURES TRADING COMMISSION UNDER THE UNITED STATES COMMODITY EXCHANGE ACT, AS AMENDED.

The securities do not constitute units of collective investment schemes within the meaning of the Swiss Federal Act on collective investment schemes ("CISA") and are not subject to the approval of, or supervision by the Swiss Financial Market Supervisory Authority ("FINMA"). Holders of the Securities are exposed to the credit risk of the issuer.

### FINAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the General Conditions and the Product Conditions applicable to each Series of Securities described herein (the "relevant Product Conditions") as set forth in the Base Prospectus relating to Turbos dated 29 June 2012 (the "Base Prospectus") as supplemented from time to time which constitutes a base prospectus for the purposes of the Prospectus Directive (Directive 2003/71/EC) (the "Prospectus Directive"). This document constitutes the Final Terms of each Series of the Securities described herein for the purposes of Article 5.4 of the Prospectus Directive and must be read in conjunction with the Base Prospectus as so supplemented. Full information on the Issuer and each Series of the Securities described herein is only available on the basis of the combination of these Final Terms and the Base Prospectus as so supplemented. The Base Prospectus as so supplemented is available for viewing at the office of the Issuer at 250 Bishopsgate, London EC2M 4AA, United Kingdom and copies may be obtained from the Issuer at that address.

These Final Terms relate to the Securities and must be read in conjunction with, and are subject to, the General Conditions and the relevant Product Conditions contained in the Base Prospectus as so supplemented. These Final Terms, the relevant Product Conditions and the General Conditions together constitute the Conditions of each Series of the Securities described herein and will be attached to any Global Security representing each such Series of the Securities. In the event of any inconsistency between these Final Terms and the General Conditions or the relevant Product Conditions, these Final Terms will govern.

The Netherlands Authority for the Financial Markets has provided the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Financial Market Authority (FMA), the Financial Services and Markets Authority (FSMA), Comisión Nacional del Mercado de Valores (CNMV), Comissão do Mercado de Valores Mobiliários (CMVM), Autorité des Marchés Financiers (AMF), Irish Financial Services Regulatory Authority (IFSRA), Commissione Nazionale per le Societa e la Borsa (CONSOB), Commission de Surveillance du Secteur Financier (CSSF), Financial Services Authority (FSA), the Financial Supervisory Authority (FIN-FSA), the Danish Financial Services Authority (Finanstilsynet), the Swedish Financial Supervisory Authority and the Financial Supervisory Authority of Norway (Finanstilsynet) with a certificate of approval attesting that the Base Prospectus has been drawn up in accordance with the Prospectus Directive.

In respect of Securities to be listed on the SIX Swiss Exchange Ltd, the Programme, together with any Final Terms, will constitute the listing prospectus pursuant to the Listing Rules of the SIX Swiss Exchange Ltd.

So far as the Issuer is aware, no person (other than the Issuer in its separate capacities as Issuer and Calculation Agent, see "Risk Factors – Actions taken by the Calculation Agent may affect the Underlying" and "Risk Factors - Actions taken by the Issuer may affect the value of the Securities" in the Base Prospectus) involved in the issue of the Turbo Certificates has an interest material to the offer.

Issuer: The Royal Bank of Scotland N.V., acting through its principal

office at Gustav Mahlerlaan 10, 1082 PP Amsterdam, The Netherlands or its London branch at 250 Bishopsgate, London

EC2M 4AA

Clearing Agents: Euroclear Amsterdam, Euroclear Bank S.A. as operator of the

Euroclear system, Clearstream Banking, société anonyme

Pricing Date(s):

Subscription Period:

Not Applicable

Not Applicable

Launch Date:

27 July 2012

Issue Date:

27 July 2012

Listing: NYSE Euronext in Amsterdam, NYSE Euronext in Paris

Listing Date: 27 July 2012

Admission to Trading: Application has been made for the Securities to be admitted to

trading on NYSE Euronext in Amsterdam with effect from 27 July 2012 and on NYSE Euronext in Paris with effect from 27 July 2012

Details of the minimum and/or Please refer to the section of the Base Prospectus entitled maximum amount of application: "General Information - Information on the Offering of the

Securities - (d) Minimum/ Maximum Application Amount"

Manner in and date on which results of

the offer are to be made public:

Please refer to the section of the Base Prospectus entitled "General Information - Information on the Offering of the Securities - (f) Details of the Manner in Which the Results of the

Initial Offer are to be Made Public"

Announcements to Holders: Delivered to Clearing Agents

Principal Agent: The Royal Bank of Scotland N.V., London branch, 250

Bishopsgate, London EC2M 4AA

Registrar: In respect of Securities cleared through CREST, Computershare

Investor Services PLC, The Pavilions, Bridgewater Road, Bristol,

BS13 8AE, England.

In respect of Securities not cleared through CREST, None

Agent(s): ABN AMRO Bank N.V., MF 2020 Kemelstede 2, P.O. Box 3200,

4800 DE Breda, The Netherlands

Calculation Agent: The Royal Bank of Scotland N.V., London branch, 250

Bishopsgate, London EC2M 4AA

Indication of Yield: Not Applicable

Form of the Securities: Dematerialised form

Ratings: Standard & Poor's Credit Market Services Europe Limited: Not

Applicable

Moody's Investors Service Limited: Not Applicable

Fitch Ratings Limited: Not Applicable

## INDEX TURBO CERTIFICATES

Series: AEX-Index® Turbo Long Certificates

Issue Price: EUR 0.75
Additional Market Disruption Events: None

Business Day: As specified in Product Condition 1
Cash Amount: As specified in Product Condition 1

Index: AEX-Index® (Bloomberg code: AEX <INDEX>)

Current Financing Level on the Launch

Date:

306.00

Current Spread on the Launch Date: 2%

Current Stop Loss Premium Rate on

the Launch Date:

2% of Current Financing Level on the Launch Date

Emerging Market Disruption Events: As specified in Product Condition 1

Entitlement: 0.1

Exercise Time: 10.00 a.m. Central European Time
Final Reference Price: As specified in Product Condition 1

Final Valuation Date: Not Applicable

Financing Level Currency: EUR

Issuer Call Commencement Date: The first Business Day following the three month period from and

including the Launch Date

Issuer Call Notice Period: One year

Maximum Premium: 5% of Current Financing Level

Maximum Spread: 3.5%

Minimum Premium: 1% of Current Financing Level

Notional Dividend Amount: Applicable

Notional Dividend Period: As specified in Product Condition 1

Relevant Currency: As specified in Product Condition 1

Relevant Number of Trading Days: For the purposes of:

Issuer Call Date: 8, or in respect of an Emerging Market

Disruption Event only, 180

Valuation Date: 8, or in respect of an Emerging Market Disruption

Event only, 180

Reset Date: 15th day

Securities Exchange: NYSE Euronext in Amsterdam

Settlement Currency: EUR

Settlement Date: Up to the fifth Business Day following the Valuation Date, the last

day of the Stop Loss Termination Valuation Period or the Issuer

Call Date, as the case may be

Standard Currency: As specified in Product Condition 1
Stop Loss Event: As specified in Product Condition 1

Stop Loss Price on the Launch Date: 313.00

Stop Loss Price Rounding:

Upwards to the nearest whole 1 Index Point where "Index Point" means the standard market quotation basis used by the Index Sponsor with respect to the Index

Stop Loss Reset Date:

15th day

Stop Loss Termination Reference

Price:

As specified in Product Condition 1

Trigger Event:

Not Applicable

Valuation Date(s):

The last Trading Day of March in each year, commencing no earlier than one year after the Launch Date

Amendment to General Conditions

and/or Product Conditions:

Not Applicable

Amendments to the Offering Procedure

for the Securities:

Not Applicable

ISIN: NL0010175337

Common Code: 78967293

Fondscode: Not Applicable

Other Securities Code: Mnemonic Code: 0463N

Sales Restriction:

The Securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and the Securities may not be exercised, offered, sold, transferred or delivered within the United States or to or for the account or benefit of any LLS person as defined in

to, or for the account or benefit of, any U.S. person as defined in Regulation S under the Securities Act. Furthermore, trading in the Securities has not been approved by the United States Commodity Futures Trading Commission under the United States Commodity Exchange Act, as amended, and no U.S. person may

at any time trade or maintain a position in the Securities.

### INFORMATION ON THE UNDERLYING

Performance of Underlying/formula/ other variable, explanation of effect on value of investment and associated risks and other information concerning the Underlying: **General:** Fluctuations in the value of the Underlying will have an effect on the value of the Securities throughout the life of the Securities and at maturity/expiration. The value of the Underlying may go down or up throughout the life of the Securities.

**Automatic Termination:** If the value or performance of the Underlying on any date meets certain specified conditions, it will affect the value of the Securities, and will potentially lead to the automatic termination of the Securities.

**Positive Correlation:** All other things being equal, positive performance of the Underlying will have a positive effect on the value of the Securities at maturity/expiration, and negative performance of the Underlying will have a negative effect on the value of the Securities at maturity/expiration.

**Entitlement Less Than 1:** Any increase in the value or performance of the Underlying will have a lesser effect on the value of the Securities at maturity/expiration than would have been the case if the Securities had been exposed to one unit of the Underlying.

**Leverage:** All other things being equal, positive or negative changes in the performance of the Underlying will have a proportionately larger effect on the value of the Securities, and therefore leverage has the potential to magnify gains or losses of the Securities.

**No Capital Protection:** All other things being equal, the value or performance of the Underlying will affect the value of the Securities at maturity/expiration, to such an extent that the value of the Securities at maturity/expiration may be zero.

Bloomberg Page: AEX <INDEX>

Page where information about the past and future performance of the Underlying and its volatility can be obtained:

Index disclaimer(s):

Euronext N.V. or its subsidiaries holds all (intellectual) proprietary rights with respect to the Index. In no way Euronext N.V. or its subsidiaries sponsors, endorses or is otherwise involved in the issue and offering of the product. Euronext N.V. or its subsidiaries disclaims any liability to any party for any inaccuracy in the data on which the Index is based, for any mistakes, errors or omissions in the calculation and.or dissemination of the Index, or for the manner in which it is applied in connection with the issue and offering thereof. 'AEX®' and 'AEX-Index®" are registered trademarks for Euronext N.V. or its subsidiaries.

Series: AEX-Index® Turbo Long Certificates

Issue Price: EUR 0.43

Additional Market Disruption Events: None

Business Day: As specified in Product Condition 1

Cash Amount: As specified in Product Condition 1

Index: AEX-Index® (Bloomberg code: AEX <INDEX>)

Current Financing Level on the Launch

Date:

309.00

Current Spread on the Launch Date: 2%

Current Stop Loss Premium Rate on

the Launch Date:

2% of Current Financing Level on the Launch Date

Emerging Market Disruption Events: As specified in Product Condition 1

Entitlement: 0.1

Exercise Time: 10.00 a.m. Central European Time
Final Reference Price: As specified in Product Condition 1

Final Valuation Date: Not Applicable

Financing Level Currency: EUR

Issuer Call Commencement Date: The first Business Day following the three month period from and

including the Launch Date

Issuer Call Notice Period: One year

Maximum Premium: 5% of Current Financing Level

Maximum Spread: 3.5%

Minimum Premium: 1% of Current Financing Level

Notional Dividend Amount: Applicable

Notional Dividend Period: As specified in Product Condition 1
Relevant Currency: As specified in Product Condition 1

Relevant Number of Trading Days: For the purposes of:

Issuer Call Date: 8, or in respect of an Emerging Market

Disruption Event only, 180

Valuation Date: 8, or in respect of an Emerging Market Disruption

Event only, 180

Reset Date: 15th day

Securities Exchange: NYSE Euronext in Amsterdam

Settlement Currency: EUR

Settlement Date: Up to the fifth Business Day following the Valuation Date, the last

day of the Stop Loss Termination Valuation Period or the Issuer

Call Date, as the case may be

Standard Currency: As specified in Product Condition 1
Stop Loss Event: As specified in Product Condition 1

Stop Loss Price on the Launch Date: 316.00

Stop Loss Price Rounding: Upwards to the nearest whole 1 Index Point where "Index Point"

means the standard market quotation basis used by the Index

Sponsor with respect to the Index

Stop Loss Reset Date: 15th day

Stop Loss Termination Reference

Price:

As specified in Product Condition 1

Trigger Event: Not Applicable

Valuation Date(s): The last Trading Day of March in each year, commencing no

earlier than one year after the Launch Date

Amendment to General Conditions

and/or Product Conditions:

Amendments to the Offering Procedure

for the Securities:

Not Applicable

Not Applicable

ISIN: NL0010175345

Common Code: 80287321

Fondscode: Not Applicable

Other Securities Code: Mnemonic Code: 0464N

Sales Restriction: The Securities have not been and will not be registered under the

United States Securities Act of 1933, as amended (the "Securities Act") and the Securities may not be exercised, offered, sold, transferred or delivered within the United States or to, or for the account or benefit of, any U.S. person as defined in Regulation S under the Securities Act. Furthermore, trading in the Securities has not been approved by the United States Commodity Futures Trading Commission under the United States Commodity Exchange Act, as amended, and no U.S. person may

at any time trade or maintain a position in the Securities.

### INFORMATION ON THE UNDERLYING

Performance of Underlying/formula/ other variable, explanation of effect on value of investment and associated risks and other information concerning the Underlying: **General:** Fluctuations in the value of the Underlying will have an effect on the value of the Securities throughout the life of the Securities and at maturity/expiration. The value of the Underlying may go down or up throughout the life of the Securities.

**Automatic Termination:** If the value or performance of the Underlying on any date meets certain specified conditions, it will affect the value of the Securities, and will potentially lead to the automatic termination of the Securities.

**Positive Correlation:** All other things being equal, positive performance of the Underlying will have a positive effect on the value of the Securities at maturity/expiration, and negative performance of the Underlying will have a negative effect on the value of the Securities at maturity/expiration.

**Entitlement Less Than 1:** Any increase in the value or performance of the Underlying will have a lesser effect on the value of the Securities at maturity/expiration than would have been the case if the Securities had been exposed to one unit of the Underlying.

**Leverage:** All other things being equal, positive or negative changes in the performance of the Underlying will have a proportionately larger effect on the value of the Securities, and

therefore leverage has the potential to magnify gains or losses of the Securities.

**No Capital Protection:** All other things being equal, the value or performance of the Underlying will affect the value of the Securities at maturity/expiration, to such an extent that the value of the Securities at maturity/expiration may be zero.

Page where information about the past and future performance of the Underlying and its volatility can be obtained:

Bloomberg Page: AEX <INDEX>

Index disclaimer(s):

Euronext N.V. or its subsidiaries holds all (intellectual) proprietary rights with respect to the Index. In no way Euronext N.V. or its subsidiaries sponsors, endorses or is otherwise involved in the issue and offering of the product. Euronext N.V. or its subsidiaries disclaims any liability to any party for any inaccuracy in the data on which the Index is based, for any mistakes, errors or omissions in the calculation and.or dissemination of the Index, or for the manner in which it is applied in connection with the issue and offering thereof. 'AEX®' and 'AEX-Index®' are registered trademarks for Euronext N.V. or its subsidiaries.

### No Significant Change and No Material Adverse Change

There has been no significant change in the trading or financial position of the Group taken as a whole since 31 December 2011 (the end of the last financial period for which audited financial information of the Group has been published); and

There has been no material adverse change in the prospects of the Group taken as a whole since 31 December 2011 (the date of the last published audited financial information of the Group).

#### RESPONSIBILITY

The Issuer accepts responsibility for the information contained in the Base Prospectus, as completed and/or amended by these Final Terms. To the best of the knowledge and belief of the Issuer (which has taken all reasonable care to ensure that such is the case) the information contained in this Base Prospectus is in accordance with the facts and does not omit anything likely to affect the import of such information. Material changes since the date of the Base Prospectus will trigger the need for a supplement under Article 16 of Directive 2003/71/EC which will be filed with both the AFM and the SIX Swiss Exchange.